Treatment and survival of patients with small cell lung cancer and brain metastasis
Journal of Neuro-Oncology · 2023
DOI: 10.1007/s11060-023-04512-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2023. Verfasst von Chi-Lu Chiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chest Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei, 112, Taiwan. clchiang@vghtpe.gov.tw. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Brain Neoplasms, Radiosurgery. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Science and Technology Council, Taiwan.
Abstract (Originalsprache)
PURPOSE: To elucidate treatment patterns and their outcomes in patients with small cell lung cancer (SCLC) and brain metastasis (BM). METHODS: In this retrospective study, patients with SCLC and BM were stratified by treatment modality into three groups: those treated with systemic therapy only, those treated with stereotactic radiosurgery (SRS) and systemic therapy, and those treated with whole-brain radiotherapy (WBRT) and systemic therapy. The primary outcomes were overall survival (OS) and time to central nervous system progression (TTCP). RESULTS: The analysis included 149 patients. After BM diagnosis, 48 patients (32.2%) received systemic therapy alone, 33 received SRS with systemic therapy, and 68 received WBRT with systemic therapy. The median OS and TTCP were 7.2 months and 8.7 months, respectively. Patients receiving WBRT with systemic therapy exhibited better intracranial control, but not better OS, than did the other patients. Key prognostic factors affecting OS were age, BM lesion count, chemotherapy, and immunotherapy. Notably, the Eastern Cooperative Oncology Group performance status and BM lesion count significantly influenced intracranial control in patients treated with SRS and systemic therapy. CONCLUSION: Although WBRT combined with systemic therapy offer better intracranial control in patients with SCLC and BM, this approach is not superior to the other approaches in terms of OS benefits. Emerging systemic therapies, such as immunotherapy, may be used as alternative or adjunctive treatments for specific patient populations. Further studies are warranted to refine treatment selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chest Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei, 112, Taiwan. clchiang@vghtpe.gov.tw.
- School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. clchiang@vghtpe.gov.tw.
- Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. clchiang@vghtpe.gov.tw.
- School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
- Department of Chest Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei, 112, Taiwan.
Förderung
- National Science and Technology Council, Taiwan
Zitieren
APA
Chiang, C. L., Yang, H. C., Liao, Y. T., Luo, Y. H., Wu, Y. H., Wu, H. M., & Chen, Y. M. (2023). Treatment and survival of patients with small cell lung cancer and brain metastasis. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-023-04512-2
Vancouver
Chiang CL, Yang HC, Liao YT, Luo YH, Wu YH, Wu HM, et al. Treatment and survival of patients with small cell lung cancer and brain metastasis. Journal of Neuro-Oncology. 2023. doi:10.1007/s11060-023-04512-2
BibTeX
@article{Chiang2023,
author = {Chiang, Chi-Lu and Yang, Huai-Che and Liao, Ying-Ting and Luo, Yung-Hung and Wu, Yuan-Hung and Wu, Hsiu-Mei and Chen, Yuh-Min},
title = {Treatment and survival of patients with small cell lung cancer and brain metastasis},
journal = {Journal of Neuro-Oncology},
year = {2023},
doi = {10.1007/s11060-023-04512-2}
}
EUVIMED